—Mkt Cap: —P/E: —
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophage…
Industry Peers
Health Care Technologyloading…
Indicators:|
Key Statistics
Company
Market Cap—
Enterprise Value198.34M USD
Revenue (TTM)5.13M USD
Gross Profit-1.96M USD
Net Income (TTM)-58.01M USD
Revenue/Share0.0430 USD
Last Price—
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees82
CountryUS
SectorHealth Care
IndustryHealth Care Technology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.71
PEG—
EV/EBITDA-4.10
EV/Revenue38.63
P/S37.16
P/B-27.03
EPS (TTM)-0.34
EPS (Forward)-0.17
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin-41.73%
Oper. Margin-964.49%
EBITDA Margin0.00%
Profit Margin-1232.68%
ROE-530.45%
ROA-143.43%
Growth
Revenue Growth51.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-46.48M USD
CapEx (TTM)197.00K USD
FCF Margin-497.13%
FCF Yield—
Net Debt-2.57M USD
Net Debt/EBITDA0.05
Balance Sheet
Debt/Equity2.36
Current Ratio1.07
Quick Ratio1.02
Book Value/Sh-0.0370 USD
Cash/Share0.1540 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)3.900 USD
Target Range2.000 USD – 9.000 USD
# Analysts5
Ownership
Shares Out.190.76M
Float140.83M
Insiders26.40%
Institutions19.37%
Short Interest
Short Ratio7.0d
Short % Float3.75%
Short % Out.3.04%
Shares Short5.94M
Short (prev mo.)5.94M
Technical
SMA 501.156 USD
SMA 2001.160 USD
Beta1.10
S&P 52W Chg28.31%
Avg Vol (30d)—
Avg Vol (10d)1.08M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—